peginterferon beta-1a Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5137 1211327-92-2

Description:

MoleculeDescription

Synonyms:

  • peginterferon beta-1a
  • plegridy
  • BIIB017
an interferon beta-1a to which a single, linear 20,000 dalton methoxy poly(ethyleneglycol)-O-2-methylpropionaldehyde molecule is covalently attached to the alpha amino group of the N-terminal amino acid residue. A possible role for IFNs in prophylaxis or early treatment of COVID-19 has been suggested to compensate for possibly insufficient endogenous IFN production. However, the efficacy and safety of IFNs for treatment or prevention of COVID-19 were not established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
8.90 mcg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 2014 FDA BIOGEN IDEC INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 515.80 24.63 201 4640 57369 46623852
Multiple sclerosis relapse 379.91 24.63 148 4693 41977 46639244
Injection site erythema 313.93 24.63 153 4688 74274 46606947
Injection site reaction 206.25 24.63 100 4741 47749 46633472
Multiple sclerosis 151.19 24.63 66 4775 24725 46656496
Device malfunction 127.30 24.63 49 4792 13325 46667896
General symptom 81.84 24.63 23 4818 2332 46678889
Injection site pruritus 64.48 24.63 44 4797 39699 46641522
Injection site bruising 54.38 24.63 38 4803 35598 46645623
Injection site rash 53.17 24.63 28 4813 15785 46665436
Injection site pain 50.86 24.63 59 4782 107093 46574128
Adverse reaction 44.31 24.63 20 4821 8070 46673151
Maternal exposure during pregnancy 42.95 24.63 53 4788 102496 46578725
Abortion spontaneous 41.22 24.63 35 4806 43611 46637610
Drug delivery system malfunction 37.94 24.63 10 4831 796 46680425
Needle fatigue 33.37 24.63 6 4835 76 46681145
Procedural anxiety 31.97 24.63 8 4833 518 46680703
Injection site swelling 29.48 24.63 28 4813 40299 46640922
Product dose omission issue 28.03 24.63 57 4784 168463 46512758
Chills 27.08 24.63 41 4800 95991 46585230
White blood cell count decreased 26.26 24.63 44 4797 112187 46569034
Injection site urticaria 26.17 24.63 16 4825 11951 46669270
Product administered to patient of inappropriate age 26.06 24.63 10 4831 2686 46678535
Magnetic resonance imaging abnormal 25.92 24.63 10 4831 2726 46678495
Balance disorder 24.84 24.63 32 4809 64489 46616732

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 284.41 40.36 76 744 25529 29926129
Multiple sclerosis relapse 128.13 40.36 34 786 10828 29940830
Injection site reaction 77.84 40.36 23 797 10737 29940921
Multiple sclerosis 72.65 40.36 20 800 7247 29944411
Injection site erythema 63.97 40.36 21 799 13813 29937845

Pharmacologic Action:

SourceCodeDescription
ATC L03AB13 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
4033770 VANDF
C3848580 UMLSCUI
D10483 KEGG_DRUG
CHEMBL2108677 ChEMBL_ID
DB09122 DRUGBANK_ID
C428112 MESH_SUPPLEMENTAL_RECORD_UI
7637 IUPHAR_LIGAND_ID
9661 INN_ID
I8309403R0 UNII
1546168 RXNORM
227899 MMSL
30489 MMSL
d08282 MMSL
015648 NDDF
706897007 SNOMEDCT_US
714201001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PlegridyPen HUMAN PRESCRIPTION DRUG LABEL 1 64406-011 INJECTION, SOLUTION 125 ug SUBCUTANEOUS BLA 27 sections
Plegridy HUMAN PRESCRIPTION DRUG LABEL 1 64406-015 INJECTION, SOLUTION 125 ug SUBCUTANEOUS BLA 27 sections
Plegridy HUMAN PRESCRIPTION DRUG LABEL 1 64406-017 INJECTION, SOLUTION 125 ug INTRAMUSCULAR BLA 27 sections